REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring > Purines (including Hydrogenated) (e.g., Adenine, Guanine, Etc.) Purines (including Hydrogenated) (e.g., Adenine, Guanine, Etc.)Purines (including Hydrogenated) (e.g., Adenine, Guanine, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027104 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are ... 01/18/07 - 20070015726 - P2y6 receptor agonists for treating lung diseases This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of ... 01/18/07 - 20070015725 - 2-azapurine compounds and their uses Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids ... 01/11/07 - 20070010476 - Therapy and diagnosis of conditions related to telomere length and/or telomerase activity Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric ... 01/11/07 - 20070010475 - Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia Use of spongosine (2-methoxyadenosine) as an analgesic, in particular for the treatment of hyperalgesia, is described. ... 01/04/07 - 20070004669 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 12/28/06 - 20060293273 - Methods, compositions, and formulations for preventing or reducing adverse effects in a patient The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a ... 12/21/06 - 20060287275 - Partial and full agonists of a1 adenosine receptors Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia. ... 12/14/06 - 20060281705 - A1 adenosine receptor agonists which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction. ... 12/07/06 - 20060276428 - A1 adenosine receptor agonists which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction. ... 11/23/06 - 20060264397 - Compositions and methods for targeting cancer cells The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine ... 11/16/06 - 20060258613 - Nucleoside derivatives for treating hepatitis c virus infection Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ... 11/16/06 - 20060258612 - Cftr channel modulators R1 to R7 represent: —, H, or carbon chains, substituted or not, which may contain heteroatoms; except for betaine. ... 10/19/06 - 20060234975 - Use of adenosine receptor agonists in therapy Use of compounds of formula: (I) wherein R is C1-4 alkoxy and X is H or OH; for the prevention, treatment, or amelioration of cancer, inflammation, auto-immune disease, ischemia-reperfusion injury, epilepsy, sepsis, septic shock, neurode-generation (including Alzheimer's Disease), muscle fatigue or muscle cramp is described. The compounds are effective at ... 10/19/06 - 20060234974 - 2,6-dihalogeno-8-substituent-purine compound and process for producing the same R1, R2 and Z are each as defined in the description, or a salt thereof, a production method thereof and the like. A 2,6-dihalogeno-8-substituted-purine compound or a salt thereof, which is useful as an intermediate for producing medicaments, can be conveniently produced from a 2,6-dihalogenopurine compound or a salt thereof, ... 09/07/06 - 20060199783 - Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-o-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside. ... 08/31/06 - 20060194756 - Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists The present invention relates to the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with under-expression of HIF-1α and/or decreased HIF-1 α activity (e.g., ischemic related disorders). The methods of ... 08/31/06 - 20060194755 - Compositions and methods for regulating an immune response in a subject The present invention relates to compositions and methods for regulating an immune response in a subject, particularly to treat a subject with a tumor, notably a solid tumor, or an infectious disease. Disclosed are methods of regulating the innate immunity in a subject, such as by regulating the activity of ... 08/17/06 - 20060183707 - Production method of 2'-deoxyguanosine compound wherein R1, R2, R4, and R5 are each independently a hydrogen atom or a hydroxyl-protecting group, and R3 and R6 are hydrogen atoms or amino-protecting groups. ... // - 2′-Deoxyguanosine compounds represented by formula (2), may be prepared by desulfurizing an 8,2′-anhydro-8-mercapto-9-β-arabinofuranosylguanine compound represented by formula (1) in a solvent in the presence of a base using nickel or a nickel alloy. - ... 08/17/06 - 20060183706 - 2-beta-modified-6-substituted adenosine analogs and their use as antiviral agents Various 2′-beta-methyl-6-substituted adenosine analogs (including 2,6-disubstituted adenosine, 8-aza-6-substituted adenosine, and 2-aza-6-substituted adenosine) are prepared by conventional and combinatorial library approaches. Contemplated compounds are particularly useful as therapeutic agents, and especially as antiviral agents. ... 08/10/06 - 20060178338 - Use of 5-substituterd nucleosides for reinforcing the apoptotic effect of cytostatic drugs The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy. ... 07/20/06 - 20060160765 - Inhibitors of nucleoside phosphorylases and nucleosidases The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including ... 07/06/06 - 20060148752 - Method of treating soild tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs The present invention relates to a method of inhibiting solid tumor cell or leukemia cell proliferation by first administering to a solid tumor cell or leukemia cell either vitamin D or a derivative thereof and subsequently administering at least one anti-metabolic nucleoside analog to the solid tumor cell or the ... 06/29/06 - 20060142237 - Method for treatment of multiple sclerosis Use of an A3 adenosine receptor agonist in the preparation of a pharmaceutical composition for the treatment of an individual suffering from multiple sclerosis. The composition is preferably orally administered. Also disclosed is a pharmaceutical composition for the treatment of multiple sclerosis that comprises an effective amount of an A3 ... 06/22/06 - 20060135464 - Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues Compositions, methods and systems for treating disordered epithelial tissues, such as is caused by pathogens and/or by toxins produced thereby. The invention relates to the use of an anti-infective and/or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such ... 06/22/06 - 20060135463 - Methods and compositions for the treatment of lupus using clofarabine This invention relates to methods of treating or preventing lupus comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate or clathrate thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing lupus comprising the administration of clofarabine or ... 06/08/06 - 20060122143 - Drug-eluting stents coated with p2y12 receptor antagonist compound The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the ... 05/11/06 - 20060100167 - Methods and compositions for the treatment of autoimmune disorders using clofarabine This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing an autoimmune disorder ... 05/11/06 - 20060100166 - Compounds for modulating the activity of exchange proteins directly activated by camp (epacs) The present invention relates to novel compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs). In particular, the present invention relates to cAMP analogues that specifically modulate the activity of Epacs. The invention further relates to pharmaceutical compositions comprising the novel compounds, and the use of ... 03/16/06 - 20060058259 - Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig ... 03/09/06 - 20060052331 - 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity wherein the symbols have the meanings given in the specification. ... 03/09/06 - 20060052330 - Partial and full agonists of a1 adenosine receptors Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction. ... 02/23/06 - 20060040887 - Method for stimulating the immune, inflammatory or neuroprotective response Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective ... 01/12/06 - 20060009416 - Methods for modulating phototoxicity The invention relates to methods for modulating photodamage via the use of collagen derived molecules which either enhance or inhibit damage caused by ultraviolet light. ... 01/12/06 - 20060009415 - Corneal epithelial migration promoter Based on research for compounds that can display a corneal epithelial migration promoting effect in ophthalmology, the present invention provides P2Y receptor agonist corneal epithelial migration promoters, such as phosphoric acid compounds having an adenosyl group, uridyl group, xanthosyl group, guanosyl group, or thymidyl group, or their salts, with excellent ... 01/12/06 - 20060009414 - Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent Methods and compositions for protecting muscarinic receptor(s) in a subject by administering at least one protective agent alone, in combination with other protective agents, or in combination with at least one neurologic agent. ... 01/12/06 - 20060009413 - Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions Methods and compositions for protecting muscarinic receptor(s) in a subject from at least one carcinogenic or toxic metal by administration of a pyrophosphate analog. Methods and compositions for preventing at least one disease induced or caused by metals compromising the function of muscarinic receptors in a subject by administration of ... 12/29/05 - 20050288249 - Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold Several lines of evidence have shown a role for the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the development of spinal hyperalgesia. However, the roles of effectors for cGMP are not fully understood in the processing of pain in the spinal cord. cGMP-dependent protein kinase (PKG) Iα but ... 12/22/05 - 20050282768 - Purine derivatives as adenosine a1 receptor agonists and methods of use thereof The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, ... 12/15/05 - 20050277614 - Methods for modulating the axonal outgrowth of central nervous system neurons Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injury and the like) and methods for inhibiting the axonal outgrowth of central nervous ... 12/08/05 - 20050272686 - Nucleotide based medicament and method of use for treatment of conditions in humans A dietary supplement comprising nucleotides in a yeast carrier alone or in combination with antioxidants, amino acids and vitamins is provided that is beneficially used for the treatment of irritable bowel syndrome, chronic diarrhea and cold or flu symptoms as well as for modulating serum HDL and LDL cholesterol levels. ... 11/10/05 - 20050250728 - Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof The efficacy of reverse transcriptase and DNA polymerase inhibitors (nucleoside analogs) in a mammalian host is enhanced by administering an effective amount of PNP inhibitor of prodrug of PNP inhibitor and/or an effective amounts of 2′-de-oxyguanosine and/or prodrugs thereof. ... 10/20/05 - 20050234009 - Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs The present invention relates to a method of inhibiting solid tumor cell or leukemia cell proliferation by first administering to a solid tumor cell or leukemia cell either vitamin D or a derivative thereof and subsequently administering at least one anti-metabolic nucleoside analog to the solid tumor cell or the ... 09/29/05 - 20050215511 - Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ... 09/29/05 - 20050215510 - Methods for preparing 7-(2'-substituted-beta-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives Disclosed are methods and intermediates for the preparation of 7-(2′-R1-substituted-β-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ... 09/15/05 - 20050203051 - Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis Cyclic di-GMP or cyclic dinucleotides thereof can be used to inhibit cancer cell proliferation or to increase cancer cell apoptosis in vitro as well as in vivo in a patient. ... 08/25/05 - 20050187181 - Use of purine nucleosides to stimulate na/k atpase and to treat or prevent shock This invention relates to methods of treating or preventing hemorrhagic and septic shock in an animal by administering inosine, guanosine, deoxyinosine, deoxyguanosine or a mixture thereof. Other purine nucleosides or analogs are described that have therapeutic use in treating or preventing shock. The invention also describes methods for increasing Na/K ... 08/11/05 - 20050176673 - Phosphonate compounds The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like. ... 08/04/05 - 20050171049 - Compounds for the treatment of ischemia The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia. ... 07/21/05 - 20050159388 - Non-nucleotide compositions and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, ... 07/21/05 - 20050159387 - In-vivo energy depleting strategies for killing drug-resistant cancer cells This invention also provides a method for treating a cancer subject comprising administering to the subject a combination of ATP-depleting agents at concentrations which deplete the ATP level to, or close to, at least 15% of normal in cancer cells wherein at least one of the ATP-depleting agents is a ... 07/07/05 - 20050148538 - Adjuvant formulations for bacterial and virus vaccines and method of making same A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with ... 06/23/05 - 20050137161 - Methods and compositions for treating hepatitis c virus A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. ... ### FreshPatents.com Support |